Portfolio gaps Nevakar is building a broad portfolio of injectable products for hospital and ambulatory care settings, indicating opportunities to position additional sterile injectable solutions to expand their product line and leverage existing sales channels.

Outsourcing potential Past asset sales to Endo and collaboration history suggest Nevakar actively partners or divests pipeline assets; BD teams can explore co-development, licensing, or manufacturing partnerships to accelerate commercialization of early-stage injectables.

Clinical unmet needs Focused on addressing unmet clinical and commercial needs of FDA-approved molecules, presenting a pathway to propose enhanced formulations or improved delivery for hospital formulary inclusion and differentiation.

Financial runway With funding of $135M and revenue in the $10–$25M range, Nevakar may seek strategic investments, partnerships, or contract manufacturing to scale production, upgrade capabilities, and expand market access.

Specialty focus As a specialty injectable and ophthalmic player with a lean team, there is opportunity to position Nevakar for niche markets, persistent engagements with KOLs and hospital systems, and targeted sales efforts around critical and ambulatory care settings.